Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;26(2):1049-1056.
doi: 10.1007/s12253-019-00659-4. Epub 2019 Apr 15.

Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy

Anna Gasinska  1 , Janusz Jaszczynski  2 , Urszula Rychlik  3 , Elżbieta Łuczynska  4 , Marek Pogodzinski  2 , Mikolaj Palaczynski  2
Affiliations

Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy

Anna Gasinska et al. Pathol Oncol Res. 2020 Apr.

Abstract

The aim of the study was to evaluate prognosis for biochemical recurrence (BR) by analysing the pathological and biological characteristics of prostate cancer (PCa) after radical prostatectomy (RP). There were 130 men with clinically localized PCa in whom pretreatment serum PSA level and Ki-67, prostate specific membrane antigen (PSMA), glucose transporter-1 (GLUT-1), vascular endothelial growth factor (VEGF), microvessel density (MVD) and human telomerase reverse transcriptase (hTERT) proteins expression, based on number of immunohistochemically positive cells (labelling index), were retrospectively studied. In order to assess the prognostic significance of analysed variables in univariate and multivariate Cox analysis, patients were dichotomized based on cut-off points chosen by receiver operating characteristic (ROC) curves. There were 83 males (63.8%) at pT stage 1-2 and 47 (36.1%) at pT stage 3-4, respectively, with median (range) age of 62.8 years (49-77), and median follow-up of 78.5 months (12-148). In 42 (32.3%) men BR was found. In univariate analysis, tumour biological features: PSA ≤ 8 ng/mL (p = 0.006), Ki-67LI ≤ 12.7% (p = 0.015), VEGFLI>11.0% (p = 0.030), and hTERTLI>6.7% (p = 0.016), but not clinicopathological parameters, appeared to be positive prognosticators for BRFS. In the Cox analysis, Ki-67 lost its significance, and clinicopathological parameters appeared to be nonsignificant. The independent negative prognostic factors for BRFS were: PSA > 8.0 ng/mL, (Hazard ratio = 2.75, p = 0.003), GLUT-1 > 19.1% (HR = 2.1, p = 0.032), VEGF≤11.0% (HR = 1, p = 0.024) and hTERT≤6.7% (HR = 1, p = 0.017). High PSA level, and GLUT-1 expression and lower VEGF and nuclear hTERT expression may indicate the great role of hypoxia in BR induction in PCa.

Keywords: Biochemical failure; GLUT-1; PSA; Prostatic carcinoma; VEGF; hTERT.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Prognostic significance of PSA (a), Ki-67 (b), VEGF (c), hTERT (d), for biochemical recurrence-free survival (BRFS) in prostate cancer patients treated with radical prostatectomy (p value from log-rank test)
See this image and copyright information in PMC

References

    1. Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, Spratt DE, den RB, Martin NE, Mouw KW, Orio PF, 3rd, Choueiri TK, Taplin ME, Trinh QD, Feng FY, Nguyen PL. Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer. Eur Urol. 2011;74:146–154. doi: 10.1016/j.eururo.2018.01.043. - DOI - PMC - PubMed
    1. Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, Spångberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlén BJ, Johansson JE. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352(19):1977–1984. doi: 10.1056/NEJMoa043739. - DOI - PubMed
    1. Duffy MJ. PSA in screening for prostate cancer: more good than harm or more harm than good? Adv Clin Chem. 2014;66:1–23. doi: 10.1016/B978-0-12-801401-1.00001-3. - DOI - PubMed
    1. Xia J., Trock B. J., Gulati R., Mallinger L., Cooperberg M. R., Carroll P. R., Carter H. B., Etzioni R. Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics. Clinical Cancer Research. 2014;20(20):5302–5310. doi: 10.1158/1078-0432.CCR-13-3366. - DOI - PMC - PubMed
    1. Shao Y-H, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB, DiPaola RS, Lu-Yao GL. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 2009;101:1280–1283. doi: 10.1093/jnci/djp262. - DOI - PMC - PubMed